Currently, several tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-based drugs have been or are being investigated for proapoptotic activity in clinical phase II and III trials in NSCLC. The gene discussed is TNFSF10; the disease is non-small cell lung carcinoma.